Abstract
The myelodysplastic/myeloproliferative neoplasms represent disorders, which at initial presentation, demonstrate overlapping features of myelodysplasia and myeloproliferation. Entities included in this group of neoplasms are chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, and myelodysplastic/ myeloproliferative neoplasm, unclassifiable (including refractory anemia with ring sideroblasts associated with marked thrombocytosis). This review discusses each of these entities separately, including their characteristic cytomorphological, immunophenotypic, cytogenetic, and molecular features, differential diagnoses, and therapeutic approaches (including targeted therapy).
Keywords: Chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, refractory anemia with ring sideroblasts associated with marked thrombocytosis
Current Cancer Therapy Reviews
Title: Myelodysplastic/Myeloproliferative Neoplasms
Volume: 8 Issue: 1
Author(s): Cherie H. Dunphy
Affiliation:
Keywords: Chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, refractory anemia with ring sideroblasts associated with marked thrombocytosis
Abstract: The myelodysplastic/myeloproliferative neoplasms represent disorders, which at initial presentation, demonstrate overlapping features of myelodysplasia and myeloproliferation. Entities included in this group of neoplasms are chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, and myelodysplastic/ myeloproliferative neoplasm, unclassifiable (including refractory anemia with ring sideroblasts associated with marked thrombocytosis). This review discusses each of these entities separately, including their characteristic cytomorphological, immunophenotypic, cytogenetic, and molecular features, differential diagnoses, and therapeutic approaches (including targeted therapy).
Export Options
About this article
Cite this article as:
H. Dunphy Cherie, Myelodysplastic/Myeloproliferative Neoplasms, Current Cancer Therapy Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339412799462530
DOI https://dx.doi.org/10.2174/157339412799462530 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands
Current Cardiology Reviews Lipid-Activated Nuclear Receptors and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Viral and Cellular Cytokines as Therapeutic Targets in AIDS-Related Lymphoproliferative Disorders
Current Drug Targets - Cardiovascular & Hematological Disorders Progress of Biological Agents on Psoriatic Arthritis
Current Pharmaceutical Biotechnology Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Current Medicinal Chemistry A Nuclear Receptor-Mediated Xenobiotic Response and Its Implication in Drug Metabolism and Host Protection
Current Drug Metabolism Role of Tyrosine Phosphatase Inhibitors in Cancer Treatment with Emphasis on SH2 Domain-Containing Tyrosine Phosphatases (SHPs)
Anti-Cancer Agents in Medicinal Chemistry Vitamin D and Vitamin D Receptor Activators in Treatment of Hypertension and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Saffron-Based Crocin Prevents Early Lesions of Liver Cancer: In vivo, In vitro and Network Analyses
Recent Patents on Anti-Cancer Drug Discovery Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry Treatment of Choroidal Neovascularization in High Myopia
Current Drug Targets Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye
Current Pharmaceutical Design Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Breast Cancer Biomarkers: Risk Assessment, Diagnosis, Prognosis, Prediction of Treatment Efficacy and Toxicity, and Recurrence
Current Pharmaceutical Design Role of Class II Nuclear Receptors in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Multitarget Network Strategies to Influence Memory and Forgetting: The Ras/Mapk Pathway as a Novel Option
Mini-Reviews in Medicinal Chemistry Protein Tyrosine Phosphatases: Strategies for Distinguishing Proteins in a Family Containing Multiple Drug Targets and Anti-Targets
Current Pharmaceutical Design